F-star market cap

Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $0.031B: $0.000B: F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in

EPS (ttm), -1.63. PE Ratio, n/a. Forward PE, n/a. Dividend, n/a.

16.03.2021

Currency in USD. Market state CLOSED According to F-star Therapeutics's financial reports the company's revenue in 2019 were 21.88M an decrease (-30%) over the years 2018 revenue that were of 30M. In 2019 the company's total earnings were -34.96M while total earnings in 2018 were 13.27M (-361.54%). Company's stock symbol is FSTX. Fri, 05 Feb 2021 The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street - Yahoo Finance Tue, 02 Feb 2021 Merck KGaA discloses 5.4% stake in F-star Therapeutics - Seeking Alpha Thu, 21 Jan 2021 F-star Therapeutics: New Biologics Platform For Immunotherapy - Seeking Alpha Wed, 20 Jan Market Cap $70,658,556.

Bid/Size. 6.82×1 · Ask/Size. 11.39×5 · Day Range. 7.55 – 8.75 · Volume / Avg. 144.1 / 384.8 · Year Range. 3.20 – 12.20 · Forward Div Yield. — · Market Cap. 76.4636

Market Cap F-star Therapeutics to Present at Upcoming Investor Conferences. Key Stock Data · P/E Ratio (TTM).

The company's market cap stands at $787.0 million. F-star Therapeutics (NASDAQ:FSTX) stock decreased by 12.87% to $8.6. As of 12:31 EST, F-star Therapeutics's stock is trading at a volume of 73.3K

Jan 21, 2021 · F-Star, with its ~$80M market capitalization, albeit with a much earlier pipeline, still has a long way to go. Upcoming clinical announcements are important as well as fundraising events ((i.e. Get the latest F-Star Therapeutics Inc (FSTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor View F-star Therapeutics' (NASDAQ:FSTX) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat.

CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. F-Star Therapeutics is rated below average in market capitalization category among related companies.

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. F-Star Therapeutics Market Capitalization vs Invested Capital relationship and correlation analysis over time. F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor View F-star Therapeutics' (NASDAQ:FSTX) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. S&P 500 3,925.43 DOW 31,961.86 F-Star Therapeutics Announces First Patient Dosed In First-In-Class FS120 Phase 1 Clinical Trial Benzinga Newsdesk Thu, 03 Dec 2020 08:06:54 -0500 62 Biggest Movers From Yesterday Lisa Levin Thu A fast and easy way to analyze US Stocks Technical analysis gauges display real-time ratings for the selected timeframes.

Market Cap F-star Therapeutics to Present at Upcoming Investor Conferences. Key Stock Data · P/E Ratio (TTM). N/A · EPS (TTM) -6.56 · Market Cap 64.31 M · Shares Outstanding. 4.32 M · Public Float.

By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments. Nov 20, 2020 · Spring Bank has been re-named F-star Therapeutics, Inc. and will commence trading on the Nasdaq Capital Market on November 23, 2020 under the ticker symbol "FSTX." F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments. Mar 05, 2021 · F-star Therapeutics, a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company.

zmeniť platobnú menu airbnb
500 000 eur na inr
kontaktné telefónne číslo pre podporu služby google gmail
obrázky bloxburgu
25 74 usd na eur
možnosti platby at & t bill

Dec 31, 2012 · F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Find the latest F-star Therapeutics, Inc. (FSTX) stock quote, history, news and other vital information to help you with your stock trading and investing. View the latest F-star Therapeutics Inc. (FSTX) stock price, news, historical charts, Market Capitalization Reflects the total market value of a company. Market Cap is calculated by Stock analysis for F-star Therapeutics Inc (SBPH) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap--1D 1M 1Y 5Y. View Full Chart Stock analysis for F-star Therapeutics Inc (FSTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap. 63.446M. Day Range FSTX | Complete F-star Therapeutics Inc. stock news by MarketWatch.